Pirjo Laakkonen

University of Helsinki — Finland

Medicine · Health Sciences

41h-index8.5kcitations238works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(61), CAR-T cell therapy research(46), Viral Infectious Diseases and Gene Expression in Insects(31), Glioma Diagnosis and Treatment(20), Angiogenesis and VEGF in Cancer(20)

Publications238 total

Therapeutic Eradication of Cancer-associated Fibroblasts Inhibits in vivo progression of Pancreatic Cancer
SSRN Electronic Journal·2026Open Access
Supplementary Figure S7 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
2025Open Access
Supplementary Figure S4 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
2025Open Access
Supplementary Figure S2 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
2025Open Access
Supplementary Figure S5 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
2025Open Access
Supplementary Figure S6 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
2025Open Access
Supplementary Figure S3 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
2025Open Access
Supplementary table S1 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
2025Open Access
Supplementary Figure S1 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
2025Open Access
Therapeutic Eradication of Cancer-associated Fibroblasts Inhibits in vivo progression of Pancreatic Cancer
2025Open Access
Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles
Advanced Science·2025· 1 citedOpen Access
CNSC-54. LEVERAGING THERAPEUTIC MODULATORS OF NEUROPLASTICITY TO REPROGRAM GLIOBLASTOMA CELL FATES
Neuro-Oncology·2025Open Access
PATH-87. Distinct cytotoxic effect of polybrene on glioblastoma subtypes
Neuro-Oncology·2025Open Access
[18F]Niacin for PET imaging glioblastoma via monocarboxylate transporter 1 mediated blood-brain barrier penetration
Nuclear Medicine and Biology·2025Open Access
ANGI-14. GLIOBLASTOMA PROGRESSION FROM TRANSCRIPTOMIC REGULATION TO BRAIN FUNCTIONAL CONNECTIVITY
Neuro-Oncology·2025Open Access
Rapid cleavage of 6-[18F]fluoronicotinic acid prosthetic group governs BT12 glioblastoma xenograft uptake: implications for radiolabeling design of biomolecules
EJNMMI Radiopharmacy and Chemistry·2025· 1 citedOpen Access
Utilizing Monocarboxylate Transporter 1-Mediated Blood–Brain Barrier Penetration for Glioblastoma Positron Emission Tomography Imaging with 6-[<sup>18</sup>F]Fluoronicotinic Acid
Molecular Pharmaceutics·2025· 3 citedOpen Access
Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates
Cancer Letters·2025· 10 citedOpen Access
Deciphering the Dialogue between Brain Tumors, Neurons, and Astrocytes
American Journal Of Pathology·2025· 4 citedOpen Access
Abstract 1704: Overcoming resistance in HER2-positive gastric and breast cancers: Efficacy of disitamab vedotin in preclinical models resistant to trastuzumab emtansine and trastuzumab deruxtecan
Cancer Research·2025· 1 cited
page 1 of 12Next →

Frequent Co-authors

Erkki Ruoslahti(8), Vadim Le Joncour(8), Heikki Joensuu(7), Maija Hyvönen(6), Harri Sihto(6), Leevi Kääriäinen(5), Juulia Enbäck(5), Kari Alitalo(4), Erkki Hölttä(4), Maria E. Åkerman(3), Marika Waltari(3), Bronislaw Pytowski(3), Kimmo Porkka(3), Johan Peränen(3), Tero Ahola(3), Olli Saksela(3), Johanna Lammi(3), Ale Närvänen(3), Olli Tynninen(3), Kaisa Lehti(3)